Autres langues Astellas Pharma Inc.

Actions

4503

JP3942400007

Produits pharmaceutiques

Marché Fermé - Japan Exchange 08:30:00 17/09/2026			Varia. 5j.	Varia. 1 janv.
2 365,00 ^JPY	+2,23%		+6,20%	+13,00%

01/09	Les laboratoires pharmaceutiques mondiaux ayant officiellement annoncé des accords de prix avec Trump	RE
01/09	La Maison Blanche conclut un accord avec neuf laboratoires pour réduire le prix des médicaments	MT

Autres langues

01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
01/09	White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies
01/09	Astellas Pharma Inc. Enters Voluntary Agreement with U.S. Government Supporting Affordable Access to Medicines
31/08	Trump announces new round of drug-pricing deals
31/08	Kyntra Bio Cuts Royalty Payments to NQ Project Phoebus for Accelerated Upfront Payment
31/08	Trump Announces Nine New Drug Pricing Deals With Pharmaceutical Companies
31/08	BeOne unterzeichnet Vereinbarung mit US-Regierung zu Medikamentenpreisen
31/08	Trump Administration Reaches Most-Favored-Nation Drug Pricing Deals With 9 Companies
31/08	Trump administration to announce drug pricing deals
28/08	Winst van Astellas mogelijk verdubbeld, maar kan het aandeel marktscepticisme afschudden?
27/08	Astellas' Profits May Have Doubled, But Can It Outrun the Street's Skepticism?
25/08	Astellas Pharma Inc. Doses First Patient In Phase 3 Study Of ASP2138 In Combination With Chemotherapy And Pembrolizumab As First-Line Treatment In Adults With Locally Advanced Unresectable Or Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma
10/08	AbCellera's menopause drug cuts hot flashes in mid-stage trial, shares surge
06/08	South African Patent Ruling In Favour Of Astellas Pharma
06/08	Japan Earnings Wrap: Kao, Astellas Pharma Rise; Taiyo Yuden Declines
05/08	Merck's Keytruda Gets Canadian Approval to Treat Muscle-Invasive Bladder Cancer
05/08	Astellas Pharma's Profit Soars 107% in Fiscal Q1
05/08	Astellas Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026
13/07	Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug
10/07	Health Care Down on Rotation Back to Tech - Health Care Roundup
10/07	Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA
10/07	Pfizer Poised for Mixed Second Quarter, RBC Says
10/07	Pfizer Inc. and Astellas Pharma Inc. Receive U.S. FDA Approval for PADCEV Plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer
30/06	Trump's push for the world's lowest drug prices hits snag with mid-sized companies
26/06	Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets